ACTIVATING THE PATIENT'S IMMUNE SYSTEM TO FIGHT CANCER

ABGSC Life Sciences Summit

Dr. Erik Digman Wiklund, CEO 19 May 2022

o OSE: targovax TRVX

IMPORTANT NOTICE AND DISCLAIMER

This report contains certain forward-looking statements based on uncertainty, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on the results of operations and the financial condition of Targovax. Such forward-looking statements reflect the current views of Targovax and are based on the information currently available to the company. Targovax cannot give any assurance as to the correctness of such statements.

There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied in these forward-looking statements. These factors include, among other things, risks or uncertainties associated with the success of future clinical trials; risks relating to personal injury or death in connection with clinical trials or following commercialization of the company's products, and liability in connection therewith; risks relating to the company's freedom to operate (competitors patents) in respect of the products it develops; risks of non-approval of patents not yet granted and the company's ability to adequately protect its intellectual property and knowhow; risks relating to obtaining regulatory approval and other regulatory risks relating to the development and future commercialization of the company's ability to successfully commercialize and gain market achieve commercial success; risks relating to the future development of the pricing environment and/or regulations for pharmaceutical products; risks relating to the company's ability to secure additional financing in the future, which may not be available on favorable terms or at all; risks relating to currency fluctuations; risks relating to the company's ability to retain key personnel; and risks relating to the impact of competition.

THE IMMUNO-ONCOLOGY REVOLUTION

> 500,000 patients treated per year
> 3,000 ongoing clinical trials
> 40% of US cancer patients eligible
> 10 approved products






3

FIRST GENERATION IMMUNO-ONCOLOGY: CHECKPOINT INHIBITORS

Cornerstone of current cancer treatment

Deep and durable responses
\$25b annual sales globally
8 products approved to date,


many more in development



targ**o**vax

THE CHALLENGE:

MAKE PD1 CHECKPOINT INHIBITORS WORK FOR MORE PATIENTS



0-40% of treated patients respond

>50%


of responding patients relapse

PD1 checkpoint inhibitor monotherapy not sufficient



5

THE SOLUTION: IMMUNE ACTIVATION BY TARGOVAX'S ONCOLYTIC VIROTHERAPY ONCOS



Reverses immuno-suppressive defence mechanisms in the tumor

Primes the patient's T-cells to target cancer cells

Delivers immune stimulatory payloads

TARGOVAX DEVELOPMENT PIPELINE

Product candidate	Preclinical Discovery IND- enabling		se 3 / 2022 Milestones
ONCOS-102 local delivery	PD1 Refractory Melanoma Combination w/anti PD1	Multi-cohort trial in planning	4Q 2022 / 1Q 2023 Initiation of phase 2 trial
	Mesothelioma Combination w/pemetrexed	/cisplatin	1H 2022 Full study data at scientific conference
	Metastatic Colorectal cance Combination w/anti PDL1	r	1H 2022 Clinical data at scientific conference
Mutant KRAS immunotherapy	Multiple Myeloma TG01 / QS-21		2H 2022 Initiation of clinical trial
circular RNA ONCOS vectors			2H 2022 Pre-clinical proof-of- concept data





Lead clinical program: ONCOS-102




PD1 REFRACTORY MARKET OPPORTUNITY GROWING UNMET NEED WITH INCREASED ANTI-PD1 USE

Incidence	~100,000 new stage III/IV cases of malignant melanoma per year in the major markets	
Unresectable	~50% recur and become unresectable Total ~50,000 patients per year	
PD1 resistance	~50% of cases become PD resistant Total ~25,000 patients per year	
Addressable	Estimated 10,000 – 20,000 patients per year addressable with intra-tumoral therapies	
Other PD1 resistance	>100,000 patients per year lung cancer >50,000 patients per year head and neck	



ONCOS-102 HAS DEMONSTRATED HIGHLY COMPETITIVE ORR OF 35% IN PD1 REFRACTORY MELANOMA






Targovax market analysis, November 2021

10

MULTIPLE EXAMPLES OF SYSTEMIC (ABSCOPAL) EFFECT NON-INJECTED LESIONS COMPLETELY DISAPPEARED IN TWO PATIENTS

Response in individual tumors

% change from baseline; injected and non-injected target lesions





- 12 of 36 (33%)
 non-injected target
 lesions reduced in size
- 8 of 15 (53%) patients
 had reduction in noninjected target lesions
- 4 of 15 patients (27%)
 with abscopal Partial
 Response according to
 RECIST 1.1 tumor
 shrinkage criteria

CASE EXAMPLE: PARTIAL RESPONSE IN PATIENT REFRACTORY TO BOTH T-VEC AND ANTI-PD1


Tumor response, 2 of 2 injected lesions



Patient characteristics					
Tumor stage at enrolment:	IV	Prior therapies:	Surgery		
	T4a, N1b, M1		Talimogene-laherparepvec (T-vec)		
			Ipilimumab		
RECIST 1.1:	PR , week 9-27		Pembrolizumab		

CASE EXAMPLE: PARTIAL RESPONSE PATIENT REFRACTORY TO T-VEC – T-CELL INFILTRATION

T-cell infiltrate, 1 of 2 injected lesions




targovax

13


STRONG INCREASE IN INFILTRATION OF T-CELLS IN RESPONDING PATIENTS

Multiplex immunofluorescence – T-cells





EVIDENCE OF SYSTEMIC TUMOR CONTROL BY ANTIGEN-SPECIFIC T-CELLS



- Sustained tumor antigen-specific T-cell responses observed in several patients by elispot analyses of PBMCs
- \circ β 2m-deficiency only observed in progressing patients
- One patient with β2m-deficient injected lesions showed response in non-injected β2m wild type lesions


targ**o**vax

GENE EXPRESSION DATA CONFIRMS IHC OBSERVATIONS AND DETAILS BROAD PRO-INFLAMMATORY TUMOR RE-PROGRAMING

DCR vs. progression

Activation of immune related gene signatures

Week 3 & 9 vs. Baseline



All patients: Broad activation of immune gene signatures relative to BL **Responders vs. non-responders:** Immune gene activation only persists in responders at week 9

RNAseq gene expression insights:

- Pro-inflammatory "hot" tumor remodeling by multiple pathways
- "Hot" tumor remodeling persists at least until week 9, following 6 ONCOS-102 injections
- Immune gene activation
 strongest and most persistent
 in responders
- Strong activation of cytotoxicity and increased expression of chemokines and cytokines



CTLA-4 IS STRONGLY UPREGULATED IN RESPONSE TO ONCOS-102 IN MELANOMA

log2fc=1.16 Day 1 / Baseline Day 1 / Baseline TIGIT p=1.13e-01 log2fc=0.96 Day 22 Day 22 =2.49e-01 Day 64 log2fc=5.22 Day 64 p=8.90e-06 log2fc=1.09 Day 1 / Baseline CTLA4 p=1.68e-01 g2fc=1.02 Day 22 >25-fold up-regulation =2.61e-01 log2fc=4.68 p=1.65e-04 Day 64 of CTLA-4 at Day 64 in responding patients LAG3 log2fc=1.18 Day 1 / Baseline p=5.65e-02 o2fc=0.56 Day 22 -4.30e-01 log21c=3.75 Day 64 p=8.78e-05 log2fc=-0.47 Day 1 / Baseline TIM3 p=4.64e-01 log2fc=-0.56 Day 22 p=4.39e-01 log2fc=2.13 Day 64 p=3.04e-02 log2fc=1.35 Day 1 / Baseline PDL1 p=1.21e-01 og2fc=0.21 Day 22 8.31e-01 log2fc=0.56 Day 64 0=6.74e-01 -2.5 0.0 2.5 5.0 Higher in progressors -fold difference (log2) Higher in responders

Expression of immune checkpoint inhibtors, tumor biopsy RNAseq, difference in PR vs. PD patients



STRONG RATIONALE FOR COMBINING ONCOS-102 WITH A CTLA-4 CHECKPOINT INHIBITOR




Reverse immunosuppression

CTLA-4 blockade depletes inhibitory regulatory T-cells both within the tumor and systemically



Enhance antitumor T-cell priming

CTLA-4 blockade enhances the priming of tumor-specific cytotoxic T-cells




Boost systemic activity

Enhanced tumor-specific T-cell priming leads to better systemic effect



NEXT STEP: MULTI-COHORT PHASE 2 TRIAL TO INCLUDE ONCOS-102 + ANTI-CTLA-4 COMBINATION



The cohorts can independently form the basis for subsequent registrational trial(s)





Circular RNA pipeline program



RNA-BASED THERAPEUTICS FACE SEVERAL CHALLENGES

Challenges for RNA-based therapies

RNA is chemically unstable


Efficient delivery of RNA drugs remains a major obstacle

Challenging to achieve sufficient spread and penetration into tumors


ONCOS solves these issues through a clinically validated DNA based delivery system that ensures local RNA expression and persistence in the tumor micro-environment



EMERGING CIRCULAR RNA TECHNOLOGY OPENS NOVEL **OPPORTUNITIES FOR THE ONCOS PLATFORM**




CIRCULAR RNA HAVE MULTIPLE ADVANTAGEOUS CHARACTERISTICS AS ANTI-CANCER THERAPEUTICS





ONCOS PROVIDES A VERSATILE, CLINICALLY VALIDATED, VECTOR SYSTEM FOR CIRCULAR RNA DELIVERY



Highly verstaile delivery system

Near term objectives for circRNA program:

- Validate advantages of circRNA
- In vitro proof-of-concept data by 2H 2022
- Solidify IP portfolio
- Generate and assess novel
 circONCOS product candidates
- Establish external collaborations



TARGOVAX' ADVANTAGE IN HOT CIRCULAR RNA SPACE

- Delivery system: The ONCOS platform provides a clinically validated delivery platform for circRNA
- Mechanistic insights: Targovax has deep understanding of ONCOS activity based on clinical patient tumor data
- **Manufacturing:** AdV manufacturing capabilities are already in place at scale, which is not the case for circRNA
- Team: Targovax has recruited key expertise led by circRNA discoverer and pionéer Dr. Thomas Hansen





Corporate strategy



MULTIPLE PATHS TO SIGNIFICANT VALUE CREATION

Value creation strategy




ONCOS-102

Out-license ONCOS-102 based on data from melanoma multi-cohort trial

- Opportunity to "knock-it-out-of-the-park" with novel, differentiated scientifically based IO combinations
- Sufficient sizing to de-risk program for big pharma/biotech partners
- Trial design deals with new FDA-requirements



KRAS program



Circular RNA

Establish collaboration studies for multiple shots on goal in KRAS cancers

- Aim to initiate a portfolio of phase 1/2 trials with multiple collaboration partners in several cancer types, opening avenues for future partnering
- Combine TG vaccination with complementary immunotherapies and KRAS G12C inhibitors

Pursue early pre-clinical circRNA partnering to expand into new indications

- IP portfolio strategy to enable broad circONCOS platform
- Demonstrate applicability for different types of payloads and disease settings
- Capitalize on current circRNA momentum



1Q FINANCIAL SNAPSHOT

Key figures



Shareholder base

	Estimated ownership ¹		
Shareholder	Shares million	Ownership	
Avanza Bank AB (nom.)	14.7	7.8 %	
HealthCap	12.4	6.6 %	
FJARDE AP-FONDEN	8.7	4.6 %	
ABN Amro Global (nom.)	6.5	3.4 %	
Nordnet Bank AB	5.3	2.8 %	
Goldman Sachs & Co (nom.)	5.2	2.8 %	
Nordea	4.5	2.4 %	
RadForsk	4.4	2.3 %	
Bækkelaget Holding	4.2	2.3 %	
Danske Bank (nom.)	2.7	1.4 %	
10 largest shareholders	66.8	36.4 %	
Other shareholders (6 289)	119.7	63.6 %	
Total shareholders	188.3	100.0 %	

1 As per 29 April 2022



TARGOVAX EXECUTIVE SUMMARY

Targovax building the next generation immune activator therapies ONCOS-102: Oncolytic immunotherapy with demonstrated clinical efficacy and excellent safety profile in multiple solid tumors and treatment combinations

Highly competitive response rate: 35% ORR in anti-PD1 refractory melanoma confirmed by deep mechanistic analyses of local and systemic immune activation

KRAS immunotherapy: Clinical-stage polyvalent mutant KRAS vaccine with high-profile collaboration network and KRAS IO concepts in discovery phase

Circular RNA: Emerging pipeline in novel RNA biology leveraging 10 years of academic research, potential game changer for cancer gene therapy

Company Financials: OSE listed since 2016, raised >USD 100M in total, cash runway until mid-2023, USD 40m market cap





Erik Digman Wiklund CEO erik.wiklund@targovax.com Lubor Gaal CFO lubor.gaal@targovax.com



STRONG, INTERNATIONAL SENIOR MANAGEMENT TEAM WITH A VERSATILE RANGE OF BACKGROUNDS



Dr Erik D Wiklund Chief Executive Officer

Former consultant in the Pharma & Healthcare practice of McKinsey & Co and various commercial and R&D roles in biotech, Previously CFO and CBO of Targovax.

PhD Cancer epigenetics and non-coding RNA



Dr Lubor Gaal Chief Financial Officer

BD and finance industry executive with 25 years experience from big pharma and biotech in Europe and the USA, incl. BMS, Bayer, Almirall and Locust Walk

PhD Molecular and cell biology



Dr Lone Ottesen Chief Medical Officer

Extensive experience across the global oncology and immuneoncology drug development spectrum with nearly 20 years from AZ, GSK and others

MD, PhD



Dr Victor Levitsky Chief Scientific Officer

Deeply experienced tumor immunology scientist from international academic and industry roles, including John's Hopkins, Roche and Molecular Partners

PhD Virology and tumor biology



Ola Melin Head of Manufacturing

25 years experience in Biologics development, manufacturing, and supply, most recently as Director of Technical Operations at OxThera AB.

BS Biochemical engineering



Dr Ingunn M Lindvig

VP Regulatory Affairs

20 years in the pharma and biotech industry with extensive experience in regulatory strategy across a range of pharmaceutical products.

PhD Physiology

